Stereochemistry | ABSOLUTE |
Molecular Formula | C27H21N3O5 |
Molecular Weight | 467.4727 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O
InChI
InChIKey=KOZFSFOOLUUIGY-SOLYNIJKSA-N
InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27+/m1/s1
Molecular Formula | C27H21N3O5 |
Molecular Weight | 467.4727 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
K-252a, a metabolite isolated from the culture broth of Nocardiopsis sp. K-252a, was found to exhibit an extremely potent inhibitory activity on protein kinase C. The IC50 value was 32.9 nM. K252a is a potent inhibitor of various protein kinases including Protein kinase A, Protein kinase C and
Protein kinase G. It acts by competition with the ATP binding site with Ki values of 18-25 nM. K252a also acts as a specific and potent inhibitor (IC50 = 3 nM) of
Trk receptors and thus selectively blocks the effects of nerve growth factor (NGF) on PC12 cells. At lower concentrations, K252a can act as a neuroprotective compound, promoting survival of primary neuronal
cultures. This alkaloid induces apoptosis and cell cycle arrest by inhibiting Cdc2 and Cdc25.4 Recently, K252a was found to improve psoriasis in a
SCID mouse-human skin model and to suppress referred mechanical hypersensitivity and neuropeptide up-regulation associated with acute pancreatitis.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
1.0 g K-252a (CT 327) cream will be applied to one target lesion twice daily
Route of Administration:
Topical
K-252a inhibited PMN PKC (IC50 = 0.58 uM), and caused a concentration-dependent (0.1-10 uM) inhibition of degranulation elicited with the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP), the lipid agonists, 5(S), 12(R)-dihydroxy-5,14-cis-8,10-trans eicosatetraenoic acid (LTB4) and acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC), and phorbol 12-myristate 13-acetate.